Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy

BACKGROUND: C3-glomerulopathy (C3G) is a rare pediatric kidney disease characterised by dysregulation of the alternative complement pathway, with glomerular deposition of C3. C3G may often present as a steroid-resistant nephrotic syndrome (SRNS), and there is no established effective therapy: the us...

Descripción completa

Detalles Bibliográficos
Autores principales: Balestra, Elia, Barbi, Egidio, Ceconi, Viola, Di Maso, Vittorio, Conversano, Ester, Pennesi, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673980/
https://www.ncbi.nlm.nih.gov/pubmed/37493956
http://dx.doi.org/10.1007/s00467-023-06088-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673980/
https://www.ncbi.nlm.nih.gov/pubmed/37493956
http://dx.doi.org/10.1007/s00467-023-06088-5

Ejemplares similares